Early-Stage Investments Propel Jump In Life Sciences Venture Capital
This article was originally published in The Tan Sheet
Executive Summary
In some cases, early venture capital appears to be substituting for the public market in providing finance not only to start but also sustain companies in specialty pharma and in-licensing, development-only businesses. At least 200 capital groups took part in the 156 recorded A rounds, and 50 participated in more than one.
You may also be interested in...
Biotech IPOs: High Tide
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.